---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017058"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:51:54.131341+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q3 revenue $160.3M (+37% YoY); GAAP EPS $0.63, non-GAAP $0.97; Board authorizes $200M buyback

## Summary
- Net product revenue $160.3M (+37% YoY); average WAKIX patients ~5,800 (+350 sequentially).
- GAAP net income $38.5M ($0.63 EPS); non-GAAP adjusted net income $58.8M ($0.97 EPS).
- Board authorized new $200M share repurchase program, replacing $125M prior program.
- Company continues to pursue idiopathic hypersomnia indication; expanded pipeline via Zynerba acquisition (Zygel for Fragile X).
- Repurchased ~1.4M shares for $50M in Q3.

## SEC filing metadata
- accession: 0001558370-23-017058
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023017058/0001558370-23-017058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023017058/hrmy-20231031x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017058
- JSON: https://secwatch.observer/filing/0001558370-23-017058.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.